Overcoming Monocyte Complexity in Pulmonary Fibrosis Progression from Onset to End-Stage

OMEGA aims to identify early mechanisms and therapeutic targets in progressive pulmonary fibrosis by studying monocyte subtypes and interstitial lung abnormalities from early to advanced disease stages.

Subsidie
€ 1.499.459
2025

Projectdetails

Introduction

Progressive pulmonary fibrosis (PF) is a debilitating and incurable disease. Scarring of the lung leads to respiratory failure, and 50% of patients die 3-5 years after diagnosis. Our understanding of the pathophysiology of PF is unfortunately limited to established and advanced stages when the extensive lung scarring is irreversible.

Project Overview

OMEGA is designed to explore new mechanisms underlying PF progression, from early to advanced disease, and propose therapies that timely target the disease before it becomes permanent. Two lines of evidence are at the core of OMEGA:

  1. I was among the first to show that circulating monocytes are strongly linked to PF pathology. However, which subtypes are important and what roles they play in PF etiology is still unknown.
  2. Interstitial lung abnormalities (ILA) are the only detectable features characterizing earlier stages of PF and can be identified in people without clinical suspicion of disease. Studying ILA provides the unique opportunity to identify early targets that would prevent progression to PF.

Research Objectives

OMEGA will first provide a detailed phenotype definition of human monocyte subtypes from early to advanced PF.

Second, it will probe mechanistically how and where the monocytes acquire a pathogenic phenotype as they journey from the bone marrow to the blood and differentiate in the fibrotic lung.

Methodology

I will use human and mouse material and state-of-the-art methodology to answer these questions. My current standing ensures direct and ample access to patient samples, clinical data, multi-disciplinary interactions, and a team of consultants/collaborators.

Goals

This collaboration will make it possible to identify how monocytes and their progenitors are involved in the progression of PF, and what pathways we can target as early as the disease starts, and as early as monocytes egress the bone marrow, to end the progression of this deadly disease.

Financiële details & Tijdlijn

Financiële details

Subsidiebedrag€ 1.499.459
Totale projectbegroting€ 1.499.459

Tijdlijn

Startdatum1-2-2025
Einddatum31-1-2030
Subsidiejaar2025

Partners & Locaties

Projectpartners

  • HELMHOLTZ ZENTRUM MUENCHEN DEUTSCHES FORSCHUNGSZENTRUM FUER GESUNDHEIT UND UMWELT GMBHpenvoerder
  • LUDWIG-MAXIMILIANS-UNIVERSITAET MUENCHEN
  • KLINIKUM DER LUDWIG-MAXIMILIANS-UNIVERSITAT MUNCHEN

Land(en)

Germany

Vergelijkbare projecten binnen European Research Council

ERC Consolid...

Deciphering fibrosis reversal mechanisms in chronic blood cancer for identification of novel predictive and therapeutic strategies

Rewind-MF aims to explore and develop innovative strategies for reversing bone marrow fibrosis in Primary Myelofibrosis, enhancing patient treatment options through advanced biological and computational methods.

€ 1.999.313
ERC Consolid...

Monocyte-to-Macrophage Trajectories After Lung Injury: Spatio-temporal investigation, molecular regulation & functional implications for lung regeneration and immunity

This project aims to elucidate the diverse roles and regulatory mechanisms of inflammatory monocyte-derived macrophages in lung injury and repair, using advanced mouse models and human organoid systems.

€ 1.999.863
ERC Starting...

Stratified Therapeutic Assessment Platform for Short Telomere related Lung Fibrosis using Patient-Derived iPSC

This project aims to develop a human preclinical model to study telomere shortening in idiopathic pulmonary fibrosis and test gene-targeted mRNA therapies for improved patient outcomes.

€ 1.499.420
ERC Starting...

Immune-stromal crosstalk in inflammation and fibrosis: Exploiting the spatiotemporal dynamics of the OSM-OSMR axis in inflammatory bowel disease to develop novel antifibrotic therapies

This project aims to investigate the role of oncostatin-M in immune-stromal interactions driving intestinal fibrosis in IBD, with the goal of identifying biomarkers and potential therapies.

€ 1.499.816
ERC Starting...

Mending sex differences: Unravelling the female predominance in pulmonary hypertension

This project aims to uncover the mechanisms behind the female predominance in pulmonary hypertension to identify new therapeutic targets and develop selective drug delivery methods for improved treatment.

€ 1.499.999

Vergelijkbare projecten uit andere regelingen

EIC Transition

Targeting OGG1 in Idiopathic Pulmonary Fibrosis

The TOPFIBRO project aims to advance OXC-201, a novel IPF treatment, through efficacy validation, safety assessments, and regulatory preparations for first-in-human studies, targeting a market launch.

€ 2.499.998
EIC Transition

Targeting cardiac fibrosis with next generation RNA therapeutics

FIBREX aims to develop an innovative ncRNA-based antisense oligonucleotide therapy targeting Meg3 to reverse cardiac fibrosis and treat heart failure, advancing towards clinical readiness.

€ 2.499.482
EIC Accelerator

Development of the first oral disease-modifying treatment for chronic obstructive pulmonary disease (COPD)

Palobiofarma aims to develop PBF-680, a first-in-class adenosine receptor antagonist, to treat COPD, targeting disease progression and seeking €30M for further clinical trials.

€ 2.476.106
EIC Transition

Macrophage-based immunotherapy of platinum-resistant ovarian cancer

The MACOV project aims to develop a groundbreaking macrophage-based therapy for platinum-resistant ovarian cancer, preparing it for Phase I clinical trials through comprehensive pre-clinical efficacy and safety studies.

€ 2.499.998
Mkb-innovati...

Ontwikkeling van liposomen met FOS, SCFA, PUFA

Liposoma Health ontwikkelt liposomale nutraceuticals met fructo-oligosacchariden en vetzuren om de gezondheid van mensen met een afwijkend microbioom te verbeteren, met focus op Parkinson, depressie en diabetes.

€ 20.000